Related Experiment Video
Updated: Dec 27, 2025
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
18.6K
Treating Brain Metastases from Breast Cancer: Outcomes after Stereotactic Radiosurgery.
T G Wilson1, T Robinson2, C MacFarlane3
1Bristol Cancer Institute, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|March 6, 2020
Summary
Stereotactic radiosurgery (SRS) for breast cancer brain metastases shows variable survival. Triple-negative breast cancer and larger tumor volumes are linked to poorer outcomes.
Area of Science:
- Oncology
- Neurosurgery
- Radiotherapy
Background:
- Stereotactic radiosurgery (SRS) offers an alternative to surgery or whole brain radiotherapy for managing brain metastases in breast cancer patients.
- Predictive factors for survival after SRS for brain metastases remain unclear, necessitating further investigation.
Purpose of the Study:
- To evaluate the overall survival of breast cancer patients with brain metastases treated with SRS at a single institution.
- To identify factors influencing survival in this patient cohort.
Main Methods:
- Retrospective analysis of consecutive breast cancer patients with brain metastases treated with SRS.
- Data collected included patient demographics, tumor characteristics, treatment details, and survival outcomes.
Main Results:
- Median overall survival post-SRS was 15.7 months. Tumor receptor status significantly impacted survival, with triple-negative breast cancer (TNBC) and ER+/HER2- subtypes showing shorter survival.
- Larger total tumor volume (>10 cm³), but not the number of metastases, was associated with worse survival.
- Stable extracranial disease at the time of SRS correlated with improved overall survival compared to progressive extracranial disease.
Conclusions:
- Overall survival in this SRS-treated breast cancer brain metastases cohort is comparable to previous studies.
- Factors predicting poorer survival include TNBC and ER+/HER2- histology, metastatic volumes exceeding 10 cm³, and progressive extracranial disease at the time of SRS.
